Credit Suisse’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Credit Suisse’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,168	Closed	-$31K	–	4720
2021 Q1	$31K	Sell	1,168 -470	-29%	-$21.4K	﹤0.01%	4247
2020 Q4	$59K	Buy	+1,638	New	+$59.2K	﹤0.01%	4240
2020 Q3	–	Sell	-2,354	Closed	-$100K	–	4183
2020 Q2	$100K	Buy	+2,354	New	+$159K	﹤0.01%	3834
2016 Q1	–	Sell	-186	Closed	-$23K	–	4381
2015 Q4	$23K	Buy	+186	New	+$123K	﹤0.01%	4169

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Credit Suisse's EVFM Position: Q2 2021 in Review

Credit Suisse sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2021, closing a stake of 1,168 shares — an estimated $31K sold.

Credit Suisse first reported a position in EVFM in Q4 2015 and held it in 4 quarters. The position peaked at $100K in Q2 2020. 81 funds tracked by Wall St. Rank hold EVFM as of Q2 2021.

Credit Suisse reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Credit Suisse sold 1,168 Evofem Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $31K.
Credit Suisse first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2015 and held it in 4 quarters.
Credit Suisse's Evofem Biosciences, Inc. Common Stock position peaked at $100K in Q2 2020.
81 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2021.

Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.